Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

Kudo M, Abou-Alfa GK, Ren Z, Heo J, Lencioni R, Arai Y, Bouattour M, Gonzalez-Carmona MA, Guo Y, Xu AB, Alves GV, Dechaphunkul A, Ho GF, Lim YN, Hu H, Liu R, Gu S, Ostwal V, Manasirisuk W, Chiu CF, Tekumalla SH, Shroff M, Dave V, Rahma O, Erinjeri JP, Fan J, EMERALD-3 Investigators

Open source

DOI: 10.1016/s1470-2045(26)00278-0
Published: 2026 Sep
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00278-0,
  title = {Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.},
  author = {Kudo M and Abou-Alfa GK and Ren Z and Heo J and Lencioni R and Arai Y and Bouattour M and Gonzalez-Carmona MA and Guo Y and Xu AB and Alves GV and Dechaphunkul A and Ho GF and Lim YN and Hu H and Liu R and Gu S and Ostwal V and Manasirisuk W and Chiu CF and Tekumalla SH and Shroff M and Dave V and Rahma O and Erinjeri JP and Fan J and EMERALD-3 Investigators},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00278-0},
  url = {https://doi.org/10.1016/s1470-2045(26)00278-0}
}

RIS

TY  - JOUR
TI  - Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
AU  - Kudo M
AU  - Abou-Alfa GK
AU  - Ren Z
AU  - Heo J
AU  - Lencioni R
AU  - Arai Y
AU  - Bouattour M
AU  - Gonzalez-Carmona MA
AU  - Guo Y
AU  - Xu AB
AU  - Alves GV
AU  - Dechaphunkul A
AU  - Ho GF
AU  - Lim YN
AU  - Hu H
AU  - Liu R
AU  - Gu S
AU  - Ostwal V
AU  - Manasirisuk W
AU  - Chiu CF
AU  - Tekumalla SH
AU  - Shroff M
AU  - Dave V
AU  - Rahma O
AU  - Erinjeri JP
AU  - Fan J
AU  - EMERALD-3 Investigators
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00278-0
UR  - https://doi.org/10.1016/s1470-2045(26)00278-0
ER  -

APA

M, K., GK, A., Z, R., J, H., R, L., Y, A., M, B., MA, G., Y, G., AB, X., GV, A., A, D., GF, H., YN, L., H, H., R, L., S, G., V, O., W, M., CF, C., SH, T., M, S., V, D., O, R., JP, E., J, F., & Investigators, E. (2026). Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00278-0

Source records

pubmed · retrieved 2026-09-26T02:47:23.847Z